Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Michael Skaff Acquires 1,353,625 Shares

Vivos Therapeutics, Inc. (NASDAQ:VVOS) major shareholder Michael Skaff purchased 1,353,625 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was acquired at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the completion of the acquisition, the insider directly owned 1,353,625 shares in the company, valued at $1,813,857.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Vivos Therapeutics Trading Up 1.5%

Shares of VVOS stock traded up $0.02 during mid-day trading on Thursday, hitting $1.32. 46,733 shares of the company’s stock were exchanged, compared to its average volume of 124,929. The stock has a market cap of $13.82 million, a price-to-earnings ratio of -0.75 and a beta of 6.94. Vivos Therapeutics, Inc. has a fifty-two week low of $1.09 and a fifty-two week high of $7.95. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31. The stock has a 50-day simple moving average of $1.45 and a two-hundred day simple moving average of $2.15.

Institutional Trading of Vivos Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Acorn Wealth Advisors LLC acquired a new position in Vivos Therapeutics in the fourth quarter valued at approximately $30,000. XTX Topco Ltd bought a new stake in shares of Vivos Therapeutics during the second quarter valued at about $65,000. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics during the second quarter worth approximately $220,000. DRW Securities LLC lifted its position in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares during the period. Finally, Connective Capital Management LLC bought a new position in Vivos Therapeutics during the 3rd quarter valued at $620,000. Institutional investors own 26.35% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on VVOS. Ascendiant Capital Markets lowered their price target on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.92.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.